Metsera

Metsera is a clinical-stage biotechnology company pioneering long-acting therapies to combat obesity and metabolic diseases. Founded in 2022 and backed by leading investors, Metsera leverages proprietary peptide engineering and delivery platforms to create novel oral and injectable treatments. Its pipeline includes incretin and non-incretin analogs, dual-agent therapies, and standout candidates like MET-233i, designed for once-monthly dosing. By offering effective, durable, and patient-friendly solutions, Metsera aims to redefine metabolic care and improve global health outcomes.